Fairvalue-Calculator Fairvalue-Calculator
EN DE

Diamond Biotechnology Co (6815) Fair Value & Analysis

Healthcare · TW · Market cap 1.2B TWD

Price31.00 TWD
Fair Value4.37 TWD
Upside-85.9%
Quality95/100
Evidence: Low Range 2.88 TWD – 5.46 TWD

Fair value as of: Jun 26, 2026

Analysis

Diamond Biotechnology Co (6815) currently trades at 31.00 TWD, while our model-based Fair Value estimate is 4.37 TWD — implying the stock looks roughly 85.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Diamond Biotechnology Co., Ltd researches, develops, manufactures, and sells medical equipment and skincare products in Taiwan and internationally. The company offers skin care products under the Timera and Diamond Beauty brands. It also leases medical equipment. Diamond Biotechnology Co., Ltd was founded in 2014 and is based in Taipei, Taiwan.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -23% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -9% Boston Scientific Corporation (B1SX34) -83% Edwards Lifesciences Corporation (EW) -53% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is Diamond Biotechnology Co (6815) undervalued?
As of Jun 26, 2026, our model estimates a fair value of 4.37 TWD versus a price of 31.00 TWD — about −86% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6815?
Our 21-model fair value for Diamond Biotechnology Co is 4.37 TWD (as of Jun 26, 2026), built from audited fundamentals. The current price is 31.00 TWD.
What is the quality score of 6815?
Diamond Biotechnology Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.